1829TiPA noninferiority trial of cabozantinib (C) comparing 60 mg vs 140 mg orally per day to evaluate the efficacy and safety in patients (pts) with progressive, metastatic medullary thyroid cancer (MTC). (23rd October 2018) - Krajewska, J; Robinson, B G; Keam, B; Capdevila, J; Klochikhin, A; Gan, H; Kapiteijn, E; Elisei, R; Partyka, J; Borgman, A E; Schlumberger, M